Compositions and methods for treating and preventing lung disease
View Patent ↗Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are SP-A peptides and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD).
1 . A pharmaceutical composition for enhancing SP-A activity in a cell, the composition comprising:
a) about 0.01% to about 5% by weight of a purified peptide, wherein the peptide is 10 amino acids in length and comprises the amino acid sequence of KEQCVE (SEQ ID NO: 9), wherein the peptide comprises at least one chemical modification;
b) a pharmaceutical carrier;
and c) an excipient comprising lactose or starch; wherein the composition is in a preparation for aerosolization.
2 . The composition of claim 1 , wherein the peptide is KEQCVEMYTD (SEQ ID NO: 4).
3 . The composition of claim 1 , wherein the cell is a lung cell.
4 . The composition of claim 1 , wherein the composition is for pulmonary delivery.
5 . A system, comprising:
a) the pharmaceutical composition of claim 1 ; and
b) a device for pulmonary delivery of said composition;
wherein said device is a metered dose inhaler, a dry powder inhaler, or a nebulizer.
6 . The composition of claim 1 , wherein the composition is for treating asthma.
7 . A method of enhancing SP-A activity in a cell or treating asthma in a subject in need thereof comprising: delivering a pharmaceutical composition to a lung cell in a subject, wherein the pharmaceutical composition comprises about 0.01% to about 5% by weight of a purified peptide, wherein the peptide is 10 amino acids in length and comprises the amino acid sequence of KEQCVE (SEQ ID NO: 9), wherein the peptide comprises at least one chemical modification, a pharmaceutical carrier, and an excipient comprising lactose or starch.
8 . The composition of claim 7 , wherein the peptide is KEQCVEMYTD (SEQ ID NO: 4).
9 . The method of claim 7 , wherein said composition reduces mucin production and/or reduces eosinophilia in said cell.
10 . The method of claim 7 , wherein said subject is obese.
11 . The method of claim 7 , wherein said peptide binds to a receptor selected from the group consisting of FC (CD16/32), Sirp-alpha, TLR-2 and EGFR.
12 . A pharmaceutical composition for enhancing SP-A activity in a cell, the composition comprising: a) about 0.01% to about 5% by weight of a purified peptide, wherein the peptide is 10 amino acids in length and comprises the amino acid sequence of KEQCVE (SEQ ID NO: 9), wherein the peptide comprises at least one chemical modification; and b) a pharmaceutical carrier, wherein the composition is in a preparation for aerosolization.